Deep Longevity will launch Accrua, a direct-to-consumer telehealth platform, across all 50 US states in October 2026, built around an AI-generated BloodAge report that estimates biological age from a routine blood panel. Quarterly re-measurement is intended to give patients and clinicians an objective marker against which to evaluate prescribed interventions, including GLP-1 therapies, peptides and hormone replacement. The model positions aging-clock output as a recurring clinical endpoint rather than a one-time test result.
Key Points
- BloodAge report estimates biological age from routine blood panel
- Quarterly re-measurement tracks response to clinician-guided therapy
- Subscription telehealth delivery planned across all 50 states
Longevity Analysis
The value of an aging clock lies not in the single number but in repeated measurement under a defined intervention — a shift from static biomarker reporting toward an interpretable feedback loop. Pairing quarterly blood-derived age estimates with metabolic and hormonal therapies gives clinicians a way to distinguish genuine physiological response from assumed benefit, provided the underlying clock remains sensitive to short-interval change. The cited association between biological age gap and mortality risk supplies the rationale; whether therapy-driven movement in that gap translates to altered outcomes remains the open question, making disciplined longitudinal tracking the operative variable.
Original published by LT Wire.